Serine-arginine protein kinase 1 (SRPK1), a determinant of angiogenesis, is upregulated in prostate cancer and correlates with disease stage and invasion. Issue 2 (23rd October 2015)

• Record Type: Journal Article
• Authors: Bullock, Nicholas; Potts, Jonathan; Simpkin, Andrew J; Koupparis, Anthony; Harper, Steve J; Oxley, Jon; Oltean, Sebastian
• Is Part Of: Journal of clinical pathology. Volume 69:Issue 2(2016)
• Page Start: 171
• Page End: 175
• Publication Date: 2015-10-23
• Subjects: PROSTATE -- CANCER -- ANGIOGENESIS; Pathology -- Periodicals; Pathology, Molecular -- Periodicals; 616.0705
• DOI: 10.1136/jclinpath-2015-203125
• Languages: English
• ISSNs: 0021-9746

Abstract

Abstract : Vascular endothelial growth factor (VEGF) undergoes alternative splicing to produce both proangiogenic and antiangiogenic isoforms. Preferential splicing of proangiogenic VEGF is determined by serine-arginine protein kinase 1 (SRPK1), which is upregulated in a number of cancers. In the present study, we aimed to investigate SRPK1 expression in prostate cancer (PCa) and its association with cancer progression. SRPK1 expression was assessed using immunohistochemistry of PCa tissue extracted from radical prostatectomy specimens of 110 patients. SRPK1 expression was significantly higher in tumour compared with benign tissue (p<0.00001) and correlated with higher pT stage (p=0.004), extracapsular extension (p=0.003) and extracapsular perineural invasion (p=0.008). Interestingly, the expression did not correlate with Gleason grade (p=0.21), suggesting that SRPK1 facilitates the development of a tumour microenvironment that favours growth and invasion (possibly through stimulating angiogenesis) while having little bearing on the morphology or function of the tumour cells themselves.